Latest news with #ImpactBioMedical
Business Insider
17 hours ago
- Business
- Business Insider
Why Is Impact BioMedical Stock (IBO) Up 200% Today?
Impact BioMedical (IBO) stock skyrocketed on Monday after the specialty biopharmaceutical and consumer healthcare company announced a merger agreement with Hong Kong-based pharmaceutical company Dr Ashleys Limited. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter These two companies have agreed to a reverse merger that will see Dr Ashleys Limited acquire Impact BioMedical, with the combined company trading under the Dr Ashleys Limited name. The Dr Ashleys management team will lead the combined company and will also create a new Board of Directors. Dr. Kanans Visvanats, director of Dr. Ashleys Limited, said, 'By integrating Impact Biomedical's impressive IP portfolio into our R&D efforts, we are poised to accelerate the development of groundbreaking therapies and expand our Impact on global health.' IBO Stock Movement Today
Globe and Mail
22-05-2025
- Business
- Globe and Mail
DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, today announced financial results for the first quarter of 2025, highlighting meaningful progress in its financial repositioning and a strong foundation for corporate execution in the coming quarters. In a quarter focused on streamlining operations and financial discipline, DSS delivered significant improvements in key financial metrics: 28% Year-Over-Year Revenue Growth: Total revenues rose sharply, fueled by a 30% increase in printed product sales and a nearly doubling of rental income from the company's real estate segment, which grew from $400,000 to $714,000. Strategic Asset Monetization: The Company completed the sale of its Plano, TX facility, for $9.5 million, contributing to $12.88 million in cash from investing activities during the quarter. Debt Reduction and Capital Discipline: DSS used proceeds from asset sales and investments to pay down over $8 million in total debt, reflecting a clear commitment to balance sheet optimization. Strengthening Shareholder Equity: Through its partner company Impact BioMedical, DSS raised $1.5 million in new equity capital during Q1. Improved Operating Cash Flow: Net cash used in operations improved from $2.15 million in Q1 2024 to $1.64 million in Q1 2025, underscoring early operational efficiencies. 'These results show clear, measurable progress in the financial realignment strategy we launched earlier this year,' said Jason Grady, CEO of DSS, Inc. 'In my January letter to shareholders, I outlined the urgent need to cut inefficiencies, strengthen our balance sheet, and lay the groundwork for sustained growth. This quarter proves that work is paying off. As we continue to streamline operations, we're now turning our attention toward execution in our core verticals and identifying smart, accretive opportunities that will drive long-term value. The foundation is in place and now we're building on it.' The Company plans to continue to showcase measurable results from initiatives in development, operations, and M&A activity as the year progresses. With a renewed focus on high-potential business units and capital allocation, DSS is positioning itself for a dynamic second half of 2025 and beyond. To read the 2025 CEO shareholder letter, visit: Forward-looking Statements: The foregoing material may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, and can be identified by the use of words such as 'may,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'believe,' 'potential,' 'should,' 'continue' or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. About DSS, Inc.: DSS, Inc. (NYSE American: DSS) is a multinational company operating businesses across multiple high-growth sectors. DSS focuses on creating, acquiring, and investing in innovative companies that drive sustainable value for its shareholders. For investor and media inquiries or additional information, please contact:
Yahoo
21-03-2025
- Business
- Yahoo
Impact Biomedical Inc. Announcement Stock Activity/Pricing
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. About Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. Safe Harbor Disclosure: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date. Investor Relations:info@ in to access your portfolio
